The science at HIVR4P 2024: The era of choice in biomedical HIV prevention
ABSTRACT Introduction HIVR4P 2024, the 5th HIV Research for Prevention Conference, took place in Lima, Peru, 6–10 October 2024. The conference focused on new developments in HIV prevention from basic research to new product development and implementation science. Methods Sessions were assigned to on...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Journal of the International AIDS Society |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jia2.70001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850072358975438848 |
|---|---|
| author | Beatriz Grinsztejn Victor Appay Linda‐Gail Bekker Chris Beyrer Deborah Donnell Jorge Sanchez Davina Canagasabey Carolina Coutinho Yonatan Ganor Vincent Muturi‐Kioi Katrina F. Ortblad Erin Cooney Gastón Devisich Paula Ellenberg Yanina Ghiglione Kevin K'Orimba Phionah Kibalama Ssemambo Natasha Tatiana Ludwig‐Barron Dieter Kenneth Mielke Ranajoy Mullick Michelle Kathini Muthui Pablo D. Radusky Emmanuel Sendaula Syed Raza Haider Tirmizi Akemi V. Matsuno Sanchez Julian Vega Roger Pebody |
| author_facet | Beatriz Grinsztejn Victor Appay Linda‐Gail Bekker Chris Beyrer Deborah Donnell Jorge Sanchez Davina Canagasabey Carolina Coutinho Yonatan Ganor Vincent Muturi‐Kioi Katrina F. Ortblad Erin Cooney Gastón Devisich Paula Ellenberg Yanina Ghiglione Kevin K'Orimba Phionah Kibalama Ssemambo Natasha Tatiana Ludwig‐Barron Dieter Kenneth Mielke Ranajoy Mullick Michelle Kathini Muthui Pablo D. Radusky Emmanuel Sendaula Syed Raza Haider Tirmizi Akemi V. Matsuno Sanchez Julian Vega Roger Pebody |
| author_sort | Beatriz Grinsztejn |
| collection | DOAJ |
| description | ABSTRACT Introduction HIVR4P 2024, the 5th HIV Research for Prevention Conference, took place in Lima, Peru, 6–10 October 2024. The conference focused on new developments in HIV prevention from basic research to new product development and implementation science. Methods Sessions were assigned to one of five tracks: basic science; pre‐exposure prophylaxis (PrEP) and antiretroviral (ARV)‐based prevention; vaccines and broadly neutralizing antibodies (bNAbs); applied and implementation science; and other prevention modalities and cross‐cutting issues. A team of rapporteurs covered each track and identified conference highlights. Results Strategies to elicit bNAb responses by vaccination are advancing to clinical trials, while combination bNAbs show promise as an alternative to ARV‐based products. There is promising diversity in the PrEP product pipeline and twice‐yearly lenacapavir has demonstrated exceptional efficacy, but barriers to widespread access and implementation remain, compounded by new challenges from the significant policy changes and funding reductions of the new US administration. Innovative ways of delivering PrEP to vulnerable communities that could benefit are being explored and, in some cases, have been successfully implemented. Discussion Choice in HIV prevention products and differentiated delivery models that enable clients to select options that meet their preferences and changing needs is essential. Additionally, the involvement of the community throughout the design, implementation and dissemination process is necessary to maximize the impact of HIV prevention. Ensuring equitable access in a rapidly changing context will involve policy changes, partnerships with local organizations and addressing social determinants that impact health outcomes. Conclusions We are in an era with more tools than ever before to prevent HIV acquisition; now, we need to facilitate collaborations between diverse stakeholders, including researchers, community members, policymakers, healthcare providers and funders. The future of HIV prevention should lie in a holistic approach that respects individual choice, enhances service accessibility and is flexible to meet evolving challenges and opportunities. However, policy changes since the conference ended have profoundly altered the HIV prevention landscape and threaten the advances described in this report. |
| format | Article |
| id | doaj-art-73be56e89aab481f8dcf5972d3a46918 |
| institution | DOAJ |
| issn | 1758-2652 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the International AIDS Society |
| spelling | doaj-art-73be56e89aab481f8dcf5972d3a469182025-08-20T02:47:06ZengWileyJournal of the International AIDS Society1758-26522025-07-01287n/an/a10.1002/jia2.70001The science at HIVR4P 2024: The era of choice in biomedical HIV preventionBeatriz Grinsztejn0Victor Appay1Linda‐Gail Bekker2Chris Beyrer3Deborah Donnell4Jorge Sanchez5Davina Canagasabey6Carolina Coutinho7Yonatan Ganor8Vincent Muturi‐Kioi9Katrina F. Ortblad10Erin Cooney11Gastón Devisich12Paula Ellenberg13Yanina Ghiglione14Kevin K'Orimba15Phionah Kibalama Ssemambo16Natasha Tatiana Ludwig‐Barron17Dieter Kenneth Mielke18Ranajoy Mullick19Michelle Kathini Muthui20Pablo D. Radusky21Emmanuel Sendaula22Syed Raza Haider Tirmizi23Akemi V. Matsuno Sanchez24Julian Vega25Roger Pebody26Fundação Oswaldo Cruz (Fiocruz)Rio de Janeiro BrazilUniversité de BordeauxBordeauxFranceDesmond Tutu HIV Centre Cape Town South AfricaDuke Global Health InstituteDurhamNorth CarolinaUSAThe Fred Hutchinson Cancer CenterSeattleWashingtonUSACentro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Universidad Nacional Mayor de San MarcosLima PerúPrimary Health Care ProgramPATHWashington DC USAFundação Oswaldo Cruz (Fiocruz)Rio de Janeiro BrazilUniversité Paris Cité, Institut CochinParisFranceIAVINairobi KenyaPublic Health Sciences DivisionFred Hutchinson Cancer CenterSeattleWashingtonUSADepartment of International HealthJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSAResearch DepartmentFundación HuéspedBuenos AiresArgentinaLife Sciences, Burnet InstituteMelbourneVictoriaAustraliaCONICET – Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS)Buenos AiresArgentinaMOSAIC, LVCT HealthNairobi KenyaMakerere University Johns Hopkins University (MU‐JHU) Research CollaborationKampalaUgandaDivision of Prevention Science, Department of MedicineUniversity of CaliforniaSan FranciscoCaliforniaUSADepartment of SurgeryDuke UniversityDurhamNorth CarolinaUSAAntibody Translational Research Program, Translational Health Science and Technology Institute, Virus Research, Therapeutics and VaccinesFaridabadIndiaBiosciences DepartmentKEMRI‐Wellcome Trust Research ProgrammeKilifiKenyaLife Sciences, Burnet InstituteMelbourneVictoriaAustraliaMonitoring and Evaluation, Reach Out Mbuya Community Health InitiativeKampalaUgandaDostana Male Health SocietyLahorePakistanCentro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Universidad Nacional Mayor de San MarcosLima PerúHospital General de Agudos “Juan A. Fernández”Buenos AiresArgentinaIAS ConsultantParisFranceABSTRACT Introduction HIVR4P 2024, the 5th HIV Research for Prevention Conference, took place in Lima, Peru, 6–10 October 2024. The conference focused on new developments in HIV prevention from basic research to new product development and implementation science. Methods Sessions were assigned to one of five tracks: basic science; pre‐exposure prophylaxis (PrEP) and antiretroviral (ARV)‐based prevention; vaccines and broadly neutralizing antibodies (bNAbs); applied and implementation science; and other prevention modalities and cross‐cutting issues. A team of rapporteurs covered each track and identified conference highlights. Results Strategies to elicit bNAb responses by vaccination are advancing to clinical trials, while combination bNAbs show promise as an alternative to ARV‐based products. There is promising diversity in the PrEP product pipeline and twice‐yearly lenacapavir has demonstrated exceptional efficacy, but barriers to widespread access and implementation remain, compounded by new challenges from the significant policy changes and funding reductions of the new US administration. Innovative ways of delivering PrEP to vulnerable communities that could benefit are being explored and, in some cases, have been successfully implemented. Discussion Choice in HIV prevention products and differentiated delivery models that enable clients to select options that meet their preferences and changing needs is essential. Additionally, the involvement of the community throughout the design, implementation and dissemination process is necessary to maximize the impact of HIV prevention. Ensuring equitable access in a rapidly changing context will involve policy changes, partnerships with local organizations and addressing social determinants that impact health outcomes. Conclusions We are in an era with more tools than ever before to prevent HIV acquisition; now, we need to facilitate collaborations between diverse stakeholders, including researchers, community members, policymakers, healthcare providers and funders. The future of HIV prevention should lie in a holistic approach that respects individual choice, enhances service accessibility and is flexible to meet evolving challenges and opportunities. However, policy changes since the conference ended have profoundly altered the HIV prevention landscape and threaten the advances described in this report.https://doi.org/10.1002/jia2.70001client choiceHIV preventionimplementation sciencepre‐exposure prophylaxispost‐exposure prophylaxisbroadly neutralizing antibodies |
| spellingShingle | Beatriz Grinsztejn Victor Appay Linda‐Gail Bekker Chris Beyrer Deborah Donnell Jorge Sanchez Davina Canagasabey Carolina Coutinho Yonatan Ganor Vincent Muturi‐Kioi Katrina F. Ortblad Erin Cooney Gastón Devisich Paula Ellenberg Yanina Ghiglione Kevin K'Orimba Phionah Kibalama Ssemambo Natasha Tatiana Ludwig‐Barron Dieter Kenneth Mielke Ranajoy Mullick Michelle Kathini Muthui Pablo D. Radusky Emmanuel Sendaula Syed Raza Haider Tirmizi Akemi V. Matsuno Sanchez Julian Vega Roger Pebody The science at HIVR4P 2024: The era of choice in biomedical HIV prevention Journal of the International AIDS Society client choice HIV prevention implementation science pre‐exposure prophylaxis post‐exposure prophylaxis broadly neutralizing antibodies |
| title | The science at HIVR4P 2024: The era of choice in biomedical HIV prevention |
| title_full | The science at HIVR4P 2024: The era of choice in biomedical HIV prevention |
| title_fullStr | The science at HIVR4P 2024: The era of choice in biomedical HIV prevention |
| title_full_unstemmed | The science at HIVR4P 2024: The era of choice in biomedical HIV prevention |
| title_short | The science at HIVR4P 2024: The era of choice in biomedical HIV prevention |
| title_sort | science at hivr4p 2024 the era of choice in biomedical hiv prevention |
| topic | client choice HIV prevention implementation science pre‐exposure prophylaxis post‐exposure prophylaxis broadly neutralizing antibodies |
| url | https://doi.org/10.1002/jia2.70001 |
| work_keys_str_mv | AT beatrizgrinsztejn thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT victorappay thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT lindagailbekker thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT chrisbeyrer thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT deborahdonnell thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT jorgesanchez thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT davinacanagasabey thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT carolinacoutinho thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT yonatanganor thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT vincentmuturikioi thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT katrinafortblad thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT erincooney thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT gastondevisich thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT paulaellenberg thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT yaninaghiglione thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT kevinkorimba thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT phionahkibalamassemambo thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT natashatatianaludwigbarron thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT dieterkennethmielke thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT ranajoymullick thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT michellekathinimuthui thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT pablodradusky thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT emmanuelsendaula thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT syedrazahaidertirmizi thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT akemivmatsunosanchez thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT julianvega thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT rogerpebody thescienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT beatrizgrinsztejn scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT victorappay scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT lindagailbekker scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT chrisbeyrer scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT deborahdonnell scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT jorgesanchez scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT davinacanagasabey scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT carolinacoutinho scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT yonatanganor scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT vincentmuturikioi scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT katrinafortblad scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT erincooney scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT gastondevisich scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT paulaellenberg scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT yaninaghiglione scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT kevinkorimba scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT phionahkibalamassemambo scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT natashatatianaludwigbarron scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT dieterkennethmielke scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT ranajoymullick scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT michellekathinimuthui scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT pablodradusky scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT emmanuelsendaula scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT syedrazahaidertirmizi scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT akemivmatsunosanchez scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT julianvega scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention AT rogerpebody scienceathivr4p2024theeraofchoiceinbiomedicalhivprevention |